

09 Jun 2024 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: BIO Notebook; ASCO roundup; data on Carvykti in community at ASCO; strong new results for tirzepatide in MASH; and orphan slowdown signals new path ahead.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 7 June 2024, including: BIO Notebook; ASCO roundup; data on Carvykti in community at ASCO; strong new results for tirzepatide in MASH; and orphan slowdown signals new path ahead.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More](#)" - Scrip, 5 Jun, 2024.)

(Also see "[ASCO Roundup: Looking For The Future Of Cancer Research](#)" - Scrip, 5 Jun, 2024.)

(Also see "[ASCO: Legend/J&J Explore Carvykti In Community](#)" - Scrip, 3 Jun, 2024.)

(Also see "[EASL: Tirzepatide Is The One To Beat In MASH](#)" - Scrip, 5 Jun, 2024.)

(Also see "[Orphan Drugs – Slowdown Signals New Paths Ahead](#)" - Scrip, 4 Jun, 2024.)

[Click here to explore this interactive content online](#) ✨

